

# **FDA Compliance Activities**

Barbara Wilimczyk-Macri

Compliance Officer Office of Pharmaceutical Quality, Division I Parsippany, NJ

> PDA Metro Chapter Conference May 2, 2019



These PowerPoint slides are the intellectual property of the U.S. Food and Drug Administration and the individual presenter and are protected under copyright Laws of the United States of America and other countries. All rights reserved.

# Agenda



- Program Alignment brief overview
- ConOps CDER and ORA
- Warning Letters and Aseptic Operations

# What was Program Alignment?



- Implemented on 5/15/2017
- Only occurred in Office of Regulatory Affairs (ORA).
- Program-based management structure that aligns staff by FDA-Regulated product.

# FDA

# Program Alignment Structure

- Seven Program Divisions
  - Office of Bioresearch Monitoring Operations (OBIMO)
  - Office of Biological Products Operations (OBPO)
  - Office of Medical Device and Radiological Health Operations (OMDRHO)
  - Office of Pharmaceutical Quality Operations (OPQO)
  - Office of Human and Animal Food Operations (OHAFO)
  - Office of Enforcement and Import Operations (OEIO)
  - Tobacco Operations Program

#### About the Office of Pharmaceutical Quality Operations



A specialized office to help protect and promote the safety and quality of human and animal drug products.


 A program within ORA's Office of Medical Products and Tobacco Operations (OMPTO)

6

- Investigators conduct foreign and domestic inspections of drug products for humans and animals
- Compliance officers and a mission support staff are assigned to the OPQO
- 7 Pharma Labs: DET, NRL, PHI, PSW, SJN, FCC, WEAC


- Advise and counsel agency leaders on pharmaceutical product field operations and emergency response activities
- Collaborates with CDER and CVM on all FDA-regulated pharmaceutical and biopharmaceutical products, and implementation of legislative mandates
- Provides technical assistance on investigational operations

# Office of Pharmaceutical Quality Operations (OPQO)



Prepared by Office of Regulatory Affairs (ORA) Division of Planning, Evaluation & Management (DPEM), Program Evaluation Branch, 2017

#### **OPQO** Division I



The Program Division Director (PDD) and District Director (DD) oversee all inspections, compliance and other related program activities.

#### Diana Amador-Toro: Division I - PDD & NWJ DD



Prepared by Office of Regulatory Affairs (ORA) Division of Planning, Evaluation & Management (DPEM), Program Evaluation Branch, 2017

FDA

#### Division I – Points of Contact



9

Division I	Connecticut,	PDD, Diana Amador Toro &	DIB, Karyn Campbell	DCB, Stephanie Durso
	Delaware,	Deputy Division Director (DDD), Craig	Mailing Address:	Mailing Address:
	District of	Swanson	US Custom House - 200 Chestnut St,	10 Waterview Blvd. 3rd Floor, Room 300
	Columbia,	Mailing Address:	Suite 901, Philadelphia, PA	Parsippany, NJ 07054
	Maine,	10 Waterview Blvd. 3rd Floor, Room 300	Office: 215-717-3731	Office: 973-331-4911
	Maryland,	Parsippany, NJ	Email: Karyn.Campbell@fda.hhs.gov	Email: Stephanie.Durso@fda.hhs.gov
	Massachusetts,	Office: 973-331-4901		
	New	Email: Diana.Amador-Toro@fda.hhs.gov	DIB, Nerizza Guerin	Recall Coordinators:
	Hampshire,		Mailing Address:	Lisa Mathew (NY and NJ)
	New Jersey,		10 Waterview Blvd 3rd Floor	Mailing Address:
	New York,		Parsippany, NJ 07054	10 Waterview Blvd 3rd Floor
	Pennsylvania,		Office: 856-290-4040	Parsippany, NJ 07054
	Rhode Island,		Email: Nerizza.Guerin@fda.hhs.gov	Office: 973-331-4917
	Vermont,			Email: lisa.mathew@fda.hhs.gov
	Virginia,		Preapproval Managers:	
	West Virginia		Alice Tsao (NWE* and NY)	Dellarese Priester (NWE*, PA, DE, MD, DO
			Mailing Address:	VA, WV)
			158-15 Liberty Avenue, Room 4046	Mailing Address: Annex I - 60 Eighth St NE
	NWE* =		Jamaica, NY 11433	Room 103, Atlanta, GA 30309
	Connecticut,		Office: 718-662-5657	Office: 215-717-3747
	Maine,		Email: <u>Alice.Tsao@fda.hhs.gov</u>	Email: dellarese.priester@fda.hhs.gov
	Massachusetts,			
	New		Maria Estrella (NJ)	
	Hampshire,		Mailing Address:	
	Rhode Island,		629 Cranbury Road	Email address for all
	Vermont		East Brunswick, NJ 08816	
			Office: 732-390-3820	correspondence, i.e. FDA
			Email: Maria.Estrella@fda.hhs.gov	483, WL Response, etc.
				ORAPHARM1 RESPONSES@fda.hhs.gov
			Gayle Lawson (PA, DE, MD, DC, VA, WV)	ORAPHARIVII_RESPONSES@108.1115.gov
			Mailing Address:	
			US Custom House - 200 Chestnut St,	
			Room 1003, Philadelphia, PA 19106	
			Office: 215-717-3737	
			Email: Gayle.Lawson@fda.hhs.gov	

# FDA

# **ORA Workflow**

- The Division is comprised of
  - Investigations Branch
  - Compliance Branch
  - Administrative Branch
- The Investigations Branch is responsible for performing at minimum: inspections, investigations, and sample collections.



# **ORA Workflow**


- Compliance Branch reviews Establishment Inspection Reports (EIRs), FDA 483, and FDA 483 responses of inspections that the Investigations Branch Management has classified as Official Action Indicated (OAI) for both domestic and foreign inspections.
- If the Compliance Officer concurs with the classification, they decide on the regulatory recommendation.
- The Compliance Officer submits a recommendation in accordance with the ConOps Agreement.

#### **ConOps Agreement**

Integration of the Facility Evaluation and Inspection Program for Human Drugs –A New Operating Model

INTEGRATION OF FDA FACILITY EVALUATION AND INSPECTION PROGRAM FOR HUMAN DRUGS: A CONCEPT OF OPERATIONS

U.S. FOOD & DRUG




CENTER FOR DRUG EVALUATION AND RESEARCH OFFICE OF REGULATORY AFFAIRS

DATED JUNE 6, 2017

#### Why Concept of Operations?





# **Regulatory Tools**



**Compliance Actions:** 

- Recalls
- Warning Letters
- Untitled Letters
- Regulatory Meetings
- Administrative Detention
- Civil/Criminal enforcement actions

FDA Issued Letters:

- Request for Additional Information (RAI)
- Request for Regulatory Meeting (domestic firms)
- Warning Letter
  Acknowledgment Letters
- Nonadherence to Consent Decree Orders

# Foreign Versus Domestic

FDA

**Domestic Inspections** 

- Typically, Regulatory Meetings held within the Division
- Warning Letters and Untitled Letters signed by the Program Division Director

Foreign Inspections

- Regulatory Meetings will be held at CDER or on a teleconference with CDER, ORA will be in attendance
- Warning Letters, Untitled Letters, and FMD 145 will be signed and issued by CDER

#### **Decisional Letters**



• No Action Indicated: Acceptable State of Compliance

https://www.fda.gov/downloads/Drugs/DevelopmentApprovalP rocess/Manufacturing/UCM606022.pdf

• Voluntary Action Indicated: Minimally Acceptable State of Compliance

https://www.fda.gov/downloads/Drugs/DevelopmentApprovalP rocess/Manufacturing/UCM606027.pdf

• Official Action Indicated: Unacceptable State of Compliance

https://www.fda.gov/downloads/Drugs/DevelopmentApprovalP rocess/Manufacturing/UCM606026.pdf

## FMD 145



#### Field Management Directive # 145

#### **Release of Establishment Inspection Reports**

- Inspections where no agency action is considered or pursued (i.e., inspections classified as No Action Indicated [NAI] or Voluntary Action Indicated [VAI] as classified by the District Inspection Branch)
- Inspections deemed closed in accordance with 21 C.F.R. § 20.64 (d)(3)
  - Inspections resulting in agency action (i.e., Warning Letter, Untitled Letter, Seizure, etc.) are not releasable until the agency deems the "matter" to be closed in accordance with 21 C.F.R. § 20.64 (d)(3).
- Under ConOps
  - Domestic Inspection Issued by ORA Division
  - Foreign Inspection Issued by CDER

# What happens if a Warning Letter is Issued??



- After the Warning Letter is issued, a redacted version, if necessary, is posted to the FDA website.
- Response to the Warning Letter is reviewed and evaluated, as per the Regulatory Procedures Manual, an Acknowledgement Letter is sent.
  - It will tell you if the response is adequate, inadequate or if we cannot determine adequacy.
- There will be a follow up inspection to verify corrective actions.
- If all corrective actions have been verified and they are adequate, a Warning Letter Close Out Letter is issued and posted to the FDA website. The status of the firm is no longer Official Action Indicated.




# Warning Letters Issued for Sterile Operations






#### Sterility Citations in WLs by FY







#### Sterility Citations in WLs by CY





CPGM 7356.002A

Sterile Drug Process Inspections

- "A recommendation for regulatory action should be submitted by the District Office when a judgment is made that the firm is not operating in a state of control and management of the firm is unwilling or unable to make adequate corrective actions in an appropriate time frame."
- Provides 16 examples of what could warrant regulatory action.



1. Contamination with filth, objectionable microorganisms, toxic chemicals or other drug chemicals; or a reasonable potential for product contamination, with demonstrated avenues of contamination such as poor aseptic methods, contact with unclean equipment, or airborne contamination.

2. Failure to assure that each batch conforms to label claims or established specifications, such as NDA, ANDA, USP monographs, and the firm's finished product specifications.

3. Distribution of product which does not conform to established specifications.

4. Lack of adequate validation of critical steps in sterilization processes, including sterilization by filtration; sterilization cycles used for drug products; and, for aseptically processed products, sterilization processes used to sterilize components (formulation and/or its ingredients, as well as containers and closures), or to sterilize equipment surfaces that contact sterile product or any elements of the product.

5. Lack of adequate validation of aseptic processing operations (media fills).



6. Failure to appropriately conduct and document investigations of discrepancies and failures of drug products or any of their components to meet specifications, especially inadequate investigations of sterility test failures, media fill failures and repeated or significant environmental or personnel monitoring results that meet or exceed action levels.

7. Facilities and equipment which do not provide adequate protection for aseptically processed product while the sterile product or sterile components are exposed to the environment. This includes both lack of robustness due to poor design, as well as failure to maintain equipment as sterile (e.g., by providing proper barriers as well as assuring adequate sterilization frequency).

8. Failure to assure a robust cleanroom disinfection program. This may include the failure to assure sufficiently detailed cleaning procedures to assure repeatability in cleaning, or failure to demonstrate the suitability and efficacy of the disinfecting agents used for the critical controlled areas and production equipment.

9. Failure of a WFI system to deliver water that consistently meets chemical, microbiological and endotoxin specifications.



10. For aseptic processing, poor employee practices that increase the risk of product contamination.

11. Failure to provide adequate training to employees who work in critical operations, such as operators on aseptic processing lines, operators responsible for initiating and checking sterilization cycles and those who perform the 100% inspection of filled injectable products.

12. Failure to perform adequate 100% inspections of injectable products for particulate matter and other defects.

13. Failure of batch records to include complete information related to the production and control of each batch, including documentation that assures environmental and personnel monitoring data and data related to the support systems, and assure quality unit review of these records prior to approval of a lot for distribution and release. For aseptically processed product, batch documentation includes records of purposeful operator interventions into critical (Class 100 / ISO 5) areas of the line. Operator intervention should be minimized as much as possible to preclude and control contamination.

14. Use of test methodology (sterility test, endotoxin test) that is not adequate or validated.



15. Lack of an adequate environmental monitoring program, that is, one that does not include dynamic monitoring during all production shifts or has not established appropriate alert and action levels and, in the case of aseptic processing, does not includ representative critical surfaces that come in contact with sterile product, containers and closures.

16. Lack of an adequate personnel monitoring program for aseptic processing operations. For example, the program does not include daily monitoring of operators' gloves and periodic monitoring of gowns; has not established appropriate limits or does not require investigations and corrective actions when limits are exceeded.



Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).

- Lack of supporting documentation
- Failure to extend investigation to other batches
- Failure to extend the investigation to all departments, too narrow in focus
- Timeliness
- Lack of a risk assessment

Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).

- Poor Aseptic practices
- Smoke studies deficiencies
- Media Fills deficiencies



Your firm failed to establish an adequate system for monitoring environmental conditions in aseptic processing areas (21 CFR 211.42(c)(10)(iv)).

- Lack of active monitoring
- Inappropriate locations
- Inappropriate frequency



Your firm failed to ensure that laboratory records included complete data derived from all tests necessary to assure compliance with established specifications and standards (21 CFR 211.194(a)).

- Failure to document results
- Incorrect results reported

# Acknowledgements



- DCB Stephanie Durso
- CSO Sydney Rosebraugh, CDER/OMQ



These PowerPoint slides are the intellectual property of the U.S. Food and Drug Administration and the individual presenter and are protected under copyright Laws of the United States of America and other countries. All rights reserved.



# **THANK YOU**